{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gamma&page=2",
    "query": {
      "intervention": "Gamma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gamma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T15:20:52.683Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01837498",
      "title": "Reversal of Neuromuscular Blockade in Thoracic Surgical Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Residual Neuromuscular Blockade"
      ],
      "interventions": [
        {
          "name": "Neostigmine",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endeavor Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 200,
      "start_date": "2014-02",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2020-02-13",
      "last_synced_at": "2026-09-13T15:20:52.683Z",
      "location_count": 1,
      "location_summary": "Evanston, Illinois",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01837498"
    },
    {
      "nct_id": "NCT00000935",
      "title": "An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "End-Stage Renal Disease",
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "Intravenous immune globulin (IVIG)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 100,
      "start_date": null,
      "completion_date": "2003-06",
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-09-13T15:20:52.683Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000935"
    },
    {
      "nct_id": "NCT04565015",
      "title": "Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immune Deficiency"
      ],
      "interventions": [
        {
          "name": "GC5107",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GC Biopharma Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "2 Years to 16 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-12-21",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2025-07-25",
      "last_synced_at": "2026-09-13T15:20:52.683Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Centennial, Colorado • Dallas, Texas + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04565015"
    },
    {
      "nct_id": "NCT05207722",
      "title": "CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic HER2 Positive Gastroesophageal Junction Cancer"
      ],
      "interventions": [
        {
          "name": "CYNK-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Human Interleukin-2",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Celularity Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1,
      "start_date": "2022-04-14",
      "completion_date": "2024-02-15",
      "has_results": false,
      "last_update_posted_date": "2024-12-12",
      "last_synced_at": "2026-09-13T15:20:52.683Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Hackensack, New Jersey",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05207722"
    },
    {
      "nct_id": "NCT01539486",
      "title": "Relationship of Preoperative Parathyroid Hormone (PTH) and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parathyroid Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 29,
      "start_date": "2010-01",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2023-09-15",
      "last_synced_at": "2026-09-13T15:20:52.683Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01539486"
    },
    {
      "nct_id": "NCT03472469",
      "title": "MAST Trial: Multi-modal Analgesic Strategies in Trauma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Nonspecific Pain Post Traumatic Injury"
      ],
      "interventions": [
        {
          "name": "Acetaminophen IV/PO",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen PO",
          "type": "DRUG"
        },
        {
          "name": "Ketorolac",
          "type": "DRUG"
        },
        {
          "name": "Celebrex",
          "type": "DRUG"
        },
        {
          "name": "Naproxen",
          "type": "DRUG"
        },
        {
          "name": "Tramadol",
          "type": "DRUG"
        },
        {
          "name": "Pregabalin",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin",
          "type": "DRUG"
        },
        {
          "name": "Lidocaine",
          "type": "DRUG"
        },
        {
          "name": "Opioids",
          "type": "DRUG"
        },
        {
          "name": "Regional anesthesia",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 1561,
      "start_date": "2018-04-02",
      "completion_date": "2019-07-03",
      "has_results": true,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-09-13T15:20:52.683Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03472469"
    },
    {
      "nct_id": "NCT02355886",
      "title": "Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Bladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "Gabapentin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 25,
      "start_date": "2015-04-22",
      "completion_date": "2019-02-28",
      "has_results": true,
      "last_update_posted_date": "2019-06-04",
      "last_synced_at": "2026-09-13T15:20:52.683Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02355886"
    },
    {
      "nct_id": "NCT04705480",
      "title": "Pregabalin vs. Gabapentin on Reducing Opioid Usage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Analgesics",
        "Gabapentin",
        "Injuries",
        "Narcotics",
        "Pain",
        "Trauma"
      ],
      "interventions": [
        {
          "name": "Pregabalin 50mg",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin 300mg",
          "type": "DRUG"
        },
        {
          "name": "Neither Pregabalin nor Gabapentin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CAMC Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2021-04-12",
      "completion_date": "2024-12-13",
      "has_results": true,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-09-13T15:20:52.683Z",
      "location_count": 1,
      "location_summary": "Charleston, West Virginia",
      "locations": [
        {
          "city": "Charleston",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04705480"
    },
    {
      "nct_id": "NCT02219373",
      "title": "Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pediatric Chronic Neuropathic Pain"
      ],
      "interventions": [
        {
          "name": "Gabapentin",
          "type": "DRUG"
        },
        {
          "name": "Oxcarbazepine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "8 Years to 18 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-06",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-09-13T15:20:52.683Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02219373"
    },
    {
      "nct_id": "NCT01005329",
      "title": "Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Adenocarcinoma",
        "Endometrial Adenosquamous Carcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Stage IA Uterine Corpus Cancer AJCC v7",
        "Stage IB Uterine Corpus Cancer AJCC v7",
        "Stage II Uterine Corpus Cancer AJCC v7",
        "Stage IIIA Uterine Corpus Cancer AJCC v7",
        "Stage IIIB Uterine Corpus Cancer AJCC v7",
        "Stage IIIC Uterine Corpus Cancer AJCC v7",
        "Stage IVA Uterine Corpus Cancer AJCC v7",
        "Stage IVB Uterine Corpus Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 34,
      "start_date": "2009-11-06",
      "completion_date": "2013-09-22",
      "has_results": true,
      "last_update_posted_date": "2018-03-15",
      "last_synced_at": "2026-09-13T15:20:52.683Z",
      "location_count": 38,
      "location_summary": "Berkeley, California • Walnut Creek, California • Colorado Springs, Colorado + 31 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01005329"
    }
  ]
}